SCHEMBL18177438

SCHEMBL18177438

COc1cccc2c1ccn2-c1cc(N)c(C(N)=O)c(NC2CCOCC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 5/20 0.43
HSP90AB1 P08238 3/20 0.43
HSP90B1 P14625 2/20 0.43
FFAR4 Q5NUL3 1/20 0.40
PTK2 Q05397 1/20 0.39
PTK2B Q14289 1/20 0.39
TRAP1 Q12931 1/20 0.36
CREBBP Q92793 1/20 0.35
SYK P43405 1/20 0.34
KCNH2 Q12809 1/20 0.34
LRRK2 Q5S007 1/20 0.34
ALK Q9UM73 1/20 0.34
FLT3 P36888 1/20 0.34
GPR119 Q8TDV5 1/20 0.33
PRMT5 O14744 1/20 0.33
WDR77 Q9BQA1 1/20 0.33
PDCD1 Q15116 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
MAPK8 P45983 3/20 0.33
MAPK9 P45984 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4581642 0.79 HSP90AA1 (0.62) HSP90AA1HSP90AB1HSP90B1TRAP1
SCHEMBL14177840 0.79 HSP90AA1 (0.62) HSP90AA1HSP90AB1HSP90B1TRAP1
SCHEMBL14197322 0.69 HSP90AA1 (0.43) HSP90AA1HSP90B1FFAR4CD274MAPK8
SCHEMBL26628779 0.66 KDM4E (0.56) LRRK2PRMT5WDR77
SCHEMBL3418050 0.63 HTR6 (0.57) FFAR4GPR119
SCHEMBL17559356 0.62 CXCR2 (0.46) LRRK2
SCHEMBL6157022 0.62 LRRK2 (0.46) KCNH2LRRK2
SCHEMBL4581868 0.62 HSP90AA1 (0.64) HSP90AA1HSP90AB1HSP90B1TRAP1
SCHEMBL17766564 0.62 JAK1 (0.45) HSP90AA1HSP90AB1HSP90B1TRAP1KCNH2
SCHEMBL6153322 0.61 FLT3 (0.47) PTK2BSYKALKFLT3MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160311795-A1 PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 CALASIA PHARMACEUTICALS, INC. 2016-10-27 US disclosed
US-20160311795-A1 PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 CALASIA PHARMACEUTICALS, INC. 2016-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160311795-A1 PYRIMIDINE DIAMINE DERIVATIVES AS INHIBITORS OF CYTOSOLIC HSP90 HSP90B1, HSP90AB2P, HSPE1 HSP90AA1 5/4885HSP90AB1 4/4885HSP90B1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.